Ascentage Pharma Group International
AAPG37.600USD
+0.400+1.08%
Horário de mercado （ET）Cotações atrasadas em 15 min
0.00Valor de mercado
--P/L TTM
Mais detalhes de Ascentage Pharma Group International Empresa
Ascentage Pharma Group International is a holding company primarily engaged in discovering, developing and commercializing therapies primarily in hematological malignancies. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The Company mainly conducts its business in the domestic market.
Informações da empresa
Código da empresaAAPG
Nome da EmpresaAscentage Pharma Group International
Data de listagemOct 28, 2019
CEODr. Dajun Yang, M.D., Ph.D.
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscal- -
Endereço68 Xinqing Road, Suzhou Industrial Park
CidadeSUZHOU
Bolsa de valoresNASDAQ Global Market Consolidated
PaísChina
Código postal- -
Telefone
Sitehttps://www.ascentage.cn/
Código da empresaAAPG
Data de listagemOct 28, 2019
CEODr. Dajun Yang, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
,
,
Senior Vice President - Global Corporate Development and Finance
Senior Vice President - Global Corporate Development and Finance
--
--
Veet Misra
Veet Misra
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Jin Cao
Mr. Jin Cao
Head - Finance
Head - Finance
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
,
,
Senior Vice President - Global Corporate Development and Finance
Senior Vice President - Global Corporate Development and Finance
--
--
Veet Misra
Veet Misra
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Monashee Investment Management, LLC
0.17%
Point72 (DIFC) Ltd
0.03%
XY Capital Ltd.
0.03%
Voloridge Investment Management, LLC
0.02%
Verition Fund Management LLC
0.01%
Other
99.75%
Investidores
Investidores
Proporção
Monashee Investment Management, LLC
0.17%
Point72 (DIFC) Ltd
0.03%
XY Capital Ltd.
0.03%
Voloridge Investment Management, LLC
0.02%
Verition Fund Management LLC
0.01%
Other
99.75%
Tipos de investidores
Investidores
Proporção
Hedge Fund
0.18%
Investment Advisor
0.06%
Investment Advisor/Hedge Fund
0.02%
Other
99.74%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
7
238.19K
0.26%
+238.19K
2025Q1
6
237.19K
0.27%
+237.19K
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Monashee Investment Management, LLC
159.94K
0.18%
+159.94K
--
Mar 31, 2025
Point72 (DIFC) Ltd
25.40K
0.03%
+25.40K
--
Mar 31, 2025
XY Capital Ltd.
23.50K
0.03%
+23.50K
--
Mar 31, 2025
Voloridge Investment Management, LLC
15.94K
0.02%
+15.94K
--
Mar 31, 2025
Verition Fund Management LLC
9.92K
0.01%
+9.92K
--
Mar 31, 2025
UBS Financial Services, Inc.
2.48K
0%
+2.48K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco Golden Dragon China ETF
0.03%
Invesco Golden Dragon China ETF
Proporção0.03%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
